UY38595A - Métodos para el tratamiento de enfermedades relacionadas con tnfa - Google Patents

Métodos para el tratamiento de enfermedades relacionadas con tnfa

Info

Publication number
UY38595A
UY38595A UY0001038595A UY38595A UY38595A UY 38595 A UY38595 A UY 38595A UY 0001038595 A UY0001038595 A UY 0001038595A UY 38595 A UY38595 A UY 38595A UY 38595 A UY38595 A UY 38595A
Authority
UY
Uruguay
Prior art keywords
methods
tnf
tnfa
treatment
related diseases
Prior art date
Application number
UY0001038595A
Other languages
English (en)
Inventor
Sun Jung Kim
Sera Kim
Jee Hye Suh
Si Young Yang
Sun Hee Lee
Joon Ho Lee
So Hye Jo
Jin Sun Jung
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of UY38595A publication Critical patent/UY38595A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de una enfermedad relacionada con TNF-a mediante la administración subcutánea de un anticuerpo que se une a TNF-a (anticuerpo anti-TNF-a) o fragmento de unión a antígeno del mismo. En comparación con la inyección intravenosa, el método de tratamiento, la composición, el kit o el uso de acuerdo con la presente invención, ofrece la ventaja de mejorar la satisfacción del paciente, al mejorar su comodidad y calidad de vida, es decir, al reducir el tiempo requerido para la administración y disminuir la estancia del paciente en el hospital.
UY0001038595A 2019-02-28 2020-02-27 Métodos para el tratamiento de enfermedades relacionadas con tnfa UY38595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20190023769 2019-02-28

Publications (1)

Publication Number Publication Date
UY38595A true UY38595A (es) 2020-09-30

Family

ID=72239651

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038595A UY38595A (es) 2019-02-28 2020-02-27 Métodos para el tratamiento de enfermedades relacionadas con tnfa

Country Status (9)

Country Link
US (1) US20220153828A1 (es)
JP (1) JP2022521996A (es)
KR (1) KR20200105439A (es)
AR (1) AR118191A1 (es)
BR (1) BR112021016913A2 (es)
CA (1) CA3130921A1 (es)
TW (1) TW202045137A (es)
UY (1) UY38595A (es)
WO (1) WO2020175954A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45562B1 (fr) 2016-06-30 2024-05-31 Celltrion Inc Préparation pharmaceutique liquide stable

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
MX361242B (es) * 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법

Also Published As

Publication number Publication date
CA3130921A1 (en) 2020-09-03
BR112021016913A2 (pt) 2021-11-03
KR20200105439A (ko) 2020-09-07
WO2020175954A1 (ko) 2020-09-03
AR118191A1 (es) 2021-09-22
US20220153828A1 (en) 2022-05-19
JP2022521996A (ja) 2022-04-13
TW202045137A (zh) 2020-12-16

Similar Documents

Publication Publication Date Title
MX2020003888A (es) Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
AR110751A1 (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
CO6270370A2 (es) Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8
EA201890182A1 (ru) Терапевтическое средство для лечения синдрома гунтера и способ его лечения
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
CO2023002206A2 (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2
UY38595A (es) Métodos para el tratamiento de enfermedades relacionadas con tnfa
CL2022001984A1 (es) Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas
PE20200013A1 (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
AR117735A1 (es) ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
DOP2020000049A (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
MX2022016087A (es) Anticuerpos que unen el tgf-alfa y la epirregulina para su uso en el tratamiento del dolor.
BR112022009798A2 (pt) Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
MX2021011711A (es) Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica.
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
EA202190504A1 (ru) Способы лечения псориаза
AR112535A1 (es) MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa
BR112021019478A2 (pt) Primeira, segunda e terceira proteínas de fusão compreendendo anticorpos anti-mesotelina, anti-cd3 e anti-egfr, anticorpos biespecífico e triespecífico, composição farmacêutica que compreende os mesmos e usos das ditas proteínas e anticorpos, bem como da dita composição farmacêutica para tratar câncer